Feasibility of Adherence to Light Therapy

  • STATUS
    Recruiting
  • End date
    Dec 31, 2022
  • participants needed
    10
  • sponsor
    University of British Columbia
Updated on 6 October 2021

Summary

In this feasibility study, we propose an important question: What factors will affect participant adherence to the daily use of light therapy for maintenance treatment of depression? To answer this question, we will conduct a pilot study of open-label treatment with light therapy in a small sample (n=10) of participants meeting eligibility criteria to determine what factors will challenge or enhance adherence to a standard light therapy protocol.

Description

Guidelines recommend at least 6-9 months of maintenance treatment to prevent relapse once patients with major depressive disorder (MDD) are in symptom remission with antidepressant treatment. However, many patients decide to discontinue antidepressants because of side effects or personal preference for a non-pharmacological treatment. Hence, a priority question for patients is whether non-pharmacological treatments can be substituted for antidepressants for maintenance treatment.

Light therapy is a safe, evidence-based, non-pharmacological treatment for MDD and seasonal affective disorder (SAD) with fewer side effects than antidepressants. The safety and efficacy of light therapy suggest that it would also be effective for maintenance treatment and relapse prevention, but there are no studies addressing this question.

Before conducting a randomized controlled trial, we want to determine whether light therapy is feasible for patients in remission with antidepressants and whether patients will adhere to standard light therapy protocols. In this feasibility study, we will enroll patients with MDD in remission who wish to discontinue their antidepressant and substitute open-label light therapy to examine adherence outcomes.

Details
Condition Major Depression in Remission
Treatment Light Therapy
Clinical Study IdentifierNCT04944758
SponsorUniversity of British Columbia
Last Modified on6 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

[1] Outpatients 19 to 65 years of age
[2] DSM-5 criteria for major depressive disorder (MDD) past or recurrent episode as determined by the Mini International Neuropsychiatric Interview
[3] taking an antidepressant for no more than six months
[4] participant desire to discontinue antidepressant treatment because of adverse effects or other reasons
[5] total score 10 on the clinician-rated Montgomery-Asberg Depression Rating Scale [MADRS]
[6] Willing and able to complete self-report and online assessments including sufficient fluency in English

Exclusion Criteria

[1] Any psychiatric diagnosis other than MDD that is considered the primary diagnosis, including Bipolar I or Bipolar-II (lifetime)
[2] MDD with psychotic features (lifetime)
[3] significant personality disorder diagnosis [e.g., borderline, antisocial]
[4] High suicidal risk, defined by clinician judgment
[5] History of drug or alcohol abuse, with a severity of at least moderate or severe within 6 months before screening
[6] Significant neurological disorders, head trauma, or other unstable medical conditions
[7] regular use of psychotropic medication other than an antidepressant or benzodiazepines (e.g., antipsychotics, mood stabilizers)
[8] history of severe withdrawal effects with antidepressant discontinuation
[9] retinal disease or other eye condition preventing use of bright light therapy
[10] use of photosensitizing medication within 1 week of baseline visit
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note